Haryana govt seeks corporate support to fund treatment for 1,100 haemophilia patients

The Haryana Government has launched a strategic appeal to corporate partners to support the treatment of nearly 1,100 registered haemophilia patients in the state. As the cost of specialised medical care continues to rise, the state’s Health and Family Welfare Department is looking to bridge the funding gap through Corporate Social Responsibility (CSR) initiatives to ensure that no patient is left without life-saving medication.

Haemophilia is a rare genetic bleeding disorder in which the blood does not clot normally due to a lack of sufficient clotting proteins, known as factors. Patients with this condition can experience spontaneous bleeding as well as prolonged bleeding following an injury or surgery. Of Haryana’s registered patients, over 800 individuals suffer from haemophilia A. For these patients, the primary treatment involves the regular infusion of clotting factors. However, these factors are exceptionally expensive, with the annual cost of treatment for a single patient ranging between Rs 7 lakh and Rs 8 lakh.

To date, the state government has remained committed to providing these essential factors on a need-based basis. While officials maintain that no patient has been denied treatment, escalating market prices and the complexities of global supply chains have placed significant strain on the government’s procurement system. This financial pressure has prompted the state to seek robust partnerships with the private sector to sustain and expand the delivery of these high-cost treatments.

“Patients are provided clotting factors free of cost on a need basis, such as before surgery or after an injury. We ensure that nobody faces a crisis, but the provision of this healthcare comes with its own challenges. The majority of patients depend on public healthcare, as treatment in the private sector can cost several lakhs. Currently, we have no PPP or CSR tie-up,” said Dr Mukta, in charge of the haemophilia programme.

It may be noted that Haryana is not only focusing on haemophilia but is also looking to strengthen its healthcare system through CSR support, following the success of the PPP model in dialysis centres. The state is currently targeting Rs 100 crore in CSR funds for the current financial year to bolster public health infrastructure and specialised care. Beyond haemophilia treatment, the Health Department is also seeking investment for advanced diagnostic tools such as digital mammography and 4K imaging systems.

Recently, a high-level strategic meeting was chaired by Dr Sumita Misra, Additional Chief Secretary, Health and Family Welfare. Addressing stakeholders, Dr Misra emphasised that corporate contributions are vital to maintaining a resilient public health system.

“By integrating corporate investment with the state’s existing network of 3,402 health facilities, Haryana aims to reduce out-of-pocket expenditure for its citizens and ensure that advanced, affordable healthcare reaches every corner of the state. CSR in healthcare should be viewed not merely as a statutory obligation but as a strategic partnership that delivers mutual benefits,” said Dr Misra.